

Info Sheet for Technical description

No. 0008

Organization

* Mandatoty fields

Name of Organization*	Metcela Inc.	
Address, City, States, Zip, Country*	Life Innovation Center 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan 210-0821	
URL	https://www.metcela.com/en/	
Brief Descriptions of Organization* (Approx. 100 words)	Metcela Inc. is a clinical-stage biotech startup based in Japan. At Metcela, we are developing cardiac stem cell-based therapy for diseases with that currently have limited therapeutic options. One of our lead pipeline, JRM-001, is autologous cardiac stem cell product for rare pediatric congenital heart disease. It was designated the Sakigake and Orphan designation by the Japanese government. JRM-001 is currently in Phase 3 randomized, controlled, multicenter trial in Japan.	
Contact address	Name*	Aiko SUGE
	Department* / Position	COO, Director
	E-mail* / TEL	cd@metcela.com

What kind of technology do you want to offer? *

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
<input checked="" type="checkbox"/> Yes	
<input type="checkbox"/> No	

Filled in by*

Date*

Aiko SUGE, COO, Metcela Inc.
2024 9/17

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. 0008

* Mandatoty fields

Title***JRM-001; Autologus Cell Therapy for Pediatric Orphan Heart Desease****Development Phase***

- | | | |
|---------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------|
| <input type="checkbox"/> Basic Research | <input type="checkbox"/> Drug Discovery | <input type="checkbox"/> Pre-Clinical |
| <input type="checkbox"/> Clinical Trial (Phase I) | <input type="checkbox"/> Clinical Trial (Phase II) | <input checked="" type="checkbox"/> Clinical Trial (Phase III) |
| <input type="checkbox"/> Review | <input type="checkbox"/> Others | |

Diesease Area*

- | | | |
|------------------------------------------|-------------------------------------------------|----------------------------------------------------|
| <input type="checkbox"/> Cancer | <input type="checkbox"/> Central nervous system | <input type="checkbox"/> Ophthalmology |
| <input type="checkbox"/> Musculoskeletal | <input type="checkbox"/> Endocrine / Metabolism | <input checked="" type="checkbox"/> Cardiovascular |
| <input type="checkbox"/> Urogenital | <input type="checkbox"/> Digestive organ | <input type="checkbox"/> Blood |
| <input type="checkbox"/> Infection | <input type="checkbox"/> Dermatology | <input type="checkbox"/> Immunity |
| <input type="checkbox"/> Otolaryngology | <input type="checkbox"/> Respiratory | <input type="checkbox"/> Others |

Description*

Metcela Inc. is a clinical-stage biotech startup based in Japan. At Metcela, we are developing cardiac stem cell-based therapy for diseases with that currently have limited therapeutic options. One of our lead pipeline, JRM-001, is autologous cardiac stem cell product for rare pediatric congenital heart disease. It was designated the Sakigake and Orphan designation by the Japanese government. JRM-001 is currently in Phase 3 randomized, controlled, multicenter trial in Japan.

Filled in by*

Aiko SUGE, COO, Metcela Inc.

Date*

2024 9/17